Physician profile
William E Stevens
NPI 1811931298
$511.89
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $42.17 · 2021: $64.57 · 2022: $147 · 2023: $90.45 · 2024: $16.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $106.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $147.20 | 2019-2023 | |
| Abbvie INC. | $121.65 | 2021-2023 | Linzess, Viberzi |
| Allergan, INC. | $57.54 | 2019-2020 | |
| Celgene Corporation | $47.38 | 2022 | |
| Merck Sharp & Dohme LLC | $38.56 | 2022 | |
| Ferring Pharmaceuticals INC. | $18.22 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.13 | 2023 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $17.78 | 2019 | |
| Integra Lifesciences Corporation | $16.31 | 2024 | Acclarent Aera |
| Siemens Medical Solutions USA, INC. | $14.75 | 2019 | |
| Alfasigma USA, INC. | $14.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Stevens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.